Iridex CEO Interviewed by The Ophthalmologist

Medical laser company, Iridex (IRIX), CEO David Bruce is interviewed on the company’s proprietary laster treatments for glaucoma.

Iridex is unique in having treatment options across the entire spectrum of glaucoma progression:

• MLT (MicroPulse Laser Trabeculoplasty) for early-stage glaucoma
• TLT (MicroPulse Transscleral Laser Therapy) for moderate-stage glaucoma
• TSCPC (Transscleral cyclophotocoagulation) using the G-Probe for late-stage glaucoma

More, Iridex’ full-suite of treatment options provides an alternative to a lifetime of expensive drops or invasive surgery.

Disclosure: I am long Iridex and might buy or sell shares at any time.